Last updated : August 2026

Research Advances in Myalgic Encephalomyelitis

This page presents the main scientific advances concerning myalgic encephalomyelitis (ME/CFS). The information is regularly updated from scientific publications, health organizations, and international research teams.

Where does research really stand?

For several decades, research on myalgic encephalomyelitis has suffered from chronic underfunding, a small number of specialized teams, and insufficient recognition.

The COVID-19 pandemic profoundly changed this situation. The emergence of Long COVID, in which a portion of patients present a clinical picture compatible with ME, led many countries to invest massively in research.

Today, hundreds of teams are working simultaneously on:

• immune mechanisms;
• neurological abnormalities;
• energy metabolism disorders;
• genetics;
• diagnostic biomarkers;
• potential treatments.

Even though no curative treatment yet exists, biological understanding of the disease is now progressing much faster than in previous decades.

A disease far more common than people think

Studies published in recent years estimate that myalgic encephalomyelitis affects approximately 0.5 to 1% of the global population.

This would represent today between 30 and 70 million people worldwide.

These estimates must nevertheless be interpreted with caution. Many patients are never diagnosed, and the criteria used still differ between studies.

Since the COVID-19 pandemic, millions of people are also developing Long COVID. A portion of them meet the diagnostic criteria for ME, which considerably strengthens scientific interest in this disease.

Why does diagnosis remain difficult?

To date, there is still no single biological test capable of diagnosing myalgic encephalomyelitis with certainty.

Diagnosis therefore relies on:

• symptom analysis;
• the presence of post-exertional malaise (PEM), a cardinal symptom;
• excluding other diseases that could explain the symptoms.

This process often requires numerous medical examinations to rule out other conditions such as certain autoimmune, endocrine, neurological, infectious, or cancer-related diseases.

Despite progress made, diagnostic delay remains several years in many countries.

Why are researchers more optimistic today?

For a long time, researchers searched for a single biomarker capable of diagnosing all patients.

Today, the strategy has changed.

International teams now believe that ME is probably made up of several biological subgroups. The goal is therefore to combine several markers (immune, genetic, metabolic, and neurological) rather than searching for a single abnormality.

This approach, made possible by advances in artificial intelligence and so-called multi-omics technologies, opens unprecedented perspectives for the coming years.

Major research tracks

Myalgic encephalomyelitis is today considered a multisystemic disease. In other words, it does not affect a single organ, but several body systems that appear to interact with each other.

Researchers now believe that several biological mechanisms combine to cause the disease.

️ 1. A deeply disrupted immune system

Many studies show that the immune system remains abnormally activated in some patients, sometimes several years after the initial infection.

Abnormalities have been observed in particular concerning:

• certain inflammatory cytokines;
• T and B lymphocytes;
• NK (Natural Killer) cells, often less effective;
• autoimmune phenomena in some patients.

These results reinforce the hypothesis that ME could be, in some people, a disease caused by an immune response that never fully returns to normal.

2. Neuro-inflammation increasingly suspected

Several studies suggest that certain immune cells in the brain, called microglia, may remain chronically activated.

This inflammation could explain:

• brain fog;
• memory problems;
• hypersensitivity to noise and light;
• the persistent sensation of exhaustion.

Modern brain imaging techniques also show perfusion and connectivity abnormalities in several brain regions.

3. Do cells produce less energy?

For several years, many teams have been studying the functioning of mitochondria, often nicknamed the "power plants" of cells.

In several groups of patients, abnormalities in energy metabolism have been observed.

Cells sometimes appear to have greater difficulty producing or using the energy needed during exertion.

This hypothesis could help explain post-exertional malaise (PEM), a characteristic symptom of ME.

However, researchers today estimate that mitochondria are probably only part of the problem, and not the sole cause of the disease.

4. Poor oxygen circulation?

Several teams are today working on microcirculation abnormalities.

In some patients, muscles and the brain may receive less oxygen during exertion, despite a heart and lungs functioning normally.

This hypothesis is compatible with:

• orthostatic intolerance;
• post-exertional malaise;
• decline in cognitive performance;
• extreme fatigue.

Research is still underway to understand precisely the origin of these vascular abnormalities.

5. The role of the gut microbiome

In recent years, numerous publications show that the gut microbiome may also play a role in the disease.

Some studies highlight:

• a decrease in certain beneficial bacteria;
• an increase in pro-inflammatory bacteria;
• intestinal metabolism abnormalities.

These findings remain exploratory, but they could help explain digestive disorders, chronic inflammation, and certain immune abnormalities.

6. Searching for a biomarker

The greatest current goal is to discover one or more biomarkers capable of rapidly diagnosing the disease.

Today, several tracks are being studied simultaneously:

• immune signatures;
• genetic profile;
• blood proteins;
• circulating RNA;
• metabolic profile;
• artificial intelligence-assisted analysis.

The idea is no longer to search for a single abnormality, but a combination of several markers capable of identifying the different subtypes of the disease.

Major international programs

For many years, research on myalgic encephalomyelitis remained largely underfunded. Since the COVID-19 pandemic, several major international programs have profoundly changed the situation. Never before have so many scientific teams worked simultaneously on this disease.

🇬🇧 DecodeME: the largest genetic study ever conducted

Launched in the United Kingdom, the DecodeME study is today the largest genetic project dedicated to ME/CFS. More than 25,000 patients agreed to provide a DNA sample to search for genetic factors associated with the disease.

In 2025, the first results identified several regions of the genome potentially involved in the development of ME. These discoveries open the way to a better understanding of the biological mechanisms of the disease.

Researchers emphasize, however, that no single "ME gene" has been discovered. It is probably a combination of several genetic and environmental factors.

🇺🇸 NIH RECOVER: understanding the link with Long COVID

In the United States, the RECOVER program, funded by the National Institutes of Health (NIH), studies the long-term consequences of SARS-CoV-2 infection.

A significant portion of patients followed present symptoms very close to those observed in myalgic encephalomyelitis:

• post-exertional malaise;
• brain fog;
• orthostatic intolerance;
• profound fatigue;
• immune disorders.

This work today makes it possible to directly compare the two diseases and accelerate discoveries.

🇩🇪 Charité Berlin

The team of Professor Carmen Scheibenbogen, at the Charité in Berlin, is today one of the most recognized in the world.

Her research focuses in particular on:

• autoantibodies;
• vascular abnormalities;
• immune disorders;
• therapeutic trials.

Work carried out in Berlin contributes significantly to evolving understanding of the disease in Europe.

🇺🇸 Open Medicine Foundation

The Open Medicine Foundation today funds several specialized research centers located in the United States, Canada, Sweden, Australia, and New Zealand.

These centers work in particular on:

• neuro-inflammation;
• mitochondria;
• biomarkers;
• artificial intelligence applied to diagnosis;
• development of new treatments.

Treatments currently under study

To date, no treatment yet makes it possible to cure myalgic encephalomyelitis. However, numerous therapeutic approaches are currently being evaluated.

None of these treatments today constitutes a validated treatment for ME. Clinical trials are still ongoing.

Why the coming years are decisive

For the first time in nearly a century, several factors are converging:

• unprecedented funding;
• thousands of researchers involved;
• international databases;
• artificial intelligence;
• lessons learned from Long COVID.

These advances raise hope for the identification of reliable biomarkers, faster diagnosis, and, ultimately, the development of targeted treatments.

Toward a new era for myalgic encephalomyelitis

For nearly a century, myalgic encephalomyelitis was a largely unknown disease, often underdiagnosed and insufficiently studied.

The situation is changing rapidly today. Advances in fundamental research, the arrival of new technologies, and global interest sparked by Long COVID open a completely new scientific period.

For the first time, researchers have the necessary means to study ME as a true complex biological disease and no longer solely as a set of unexplained symptoms.

Toward faster and more precise diagnosis

One of the major challenges of the coming years will be to considerably reduce diagnostic delay.

Future diagnostic tools could combine several elements:

• blood markers;
• immune signatures;
• metabolic profiles;
• genetic data;
• artificial intelligence-assisted analyses.

This approach would not only identify patients more rapidly, but also better understand the different biological profiles present in the disease.

Ultimately, the goal is to move from a diagnosis based mainly on excluding other diseases to true biological confirmation.

Toward personalized treatments

One of the major changes in current research is the gradual abandonment of the idea that there would be a single cause and a single treatment valid for all patients.

Researchers are now moving toward personalized medicine, adapted to the different biological mechanisms involved.

Some patients may present a predominantly immune profile, others damage that is more metabolic, vascular, neurological, or linked to autonomic nervous system regulation abnormalities.

This new approach could make it possible, in the coming years, to develop treatments precisely targeting the mechanisms present in each group of patients.

Artificial intelligence: a new tool to accelerate discoveries

Artificial intelligence occupies an increasingly important place in medical research.

In ME, it could help researchers analyze considerable quantities of data:

• complete genomes;
• immune profiles;
• metabolic analyses;
• clinical data;
• treatment responses.

The goal is not to replace researchers or physicians, but to detect complex biological relationships that would be impossible to identify through human analysis alone.

Combined with large international databases, artificial intelligence could become a major accelerator in the discovery of biomarkers and treatments.

A disease finally emerging from the shadows

Beyond scientific advances, recognition of ME/CFS also represents a major change.

For a long time, millions of people lived with an invisible disease, without a clear diagnosis, without sufficient recognition, and with limited care options.

Today, research is gradually providing answers to questions that patients have carried for decades.

The road remains long. No curative treatment is yet available, and many scientific questions remain unanswered.

But the current momentum is different. The disease is being studied, biological mechanisms are beginning to be understood, and the international scientific community is now working to build solutions.

Main references

• National Institutes of Health (NIH)– ME/CFS and RECOVER research programs
• Centers for Disease Control and Prevention (CDC)– scientific information on ME/CFS
• National Institute for Health and Care Excellence (NICE)– Guideline NG206: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome
• DecodeME– international genetic study on ME/CFS
• Open Medicine Foundation– international biomedical research programs
• Charité Fatigue Center Berlin– immunological and therapeutic research

Research is advancing. Recognition is progressing. And behind every discovery, there are millions of people who are finally waiting for answers.